Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis

Neurology

Volumn 70, Issue 6, 2008, Pages 431-439

  Sakai, Y ^a,b   Dobson, C ^a   Diksic, M ^a   Aube M ^a   Hamel, E ^a  

^a MCGILL UNIVERSITY   (Canada)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; N METHYLTRYPTOPHAN; SEROTONIN; SUMATRIPTAN; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; SEROTONIN AGONIST; TRYPTOPHAN; TRYPTOPHAN METHYL ESTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MIGRAINE; NEGATIVE FEEDBACK; NEUROTRANSMISSION; PAIN ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; BRAIN; BRAIN LEVEL; CLINICAL TRIAL; DRUG EFFECT; FEEDBACK SYSTEM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING; SYNAPTIC TRANSMISSION; UPREGULATION;

ADULT; BRAIN; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CEREBRAL CORTEX; FEEDBACK, BIOCHEMICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; TRYPTOPHAN; UP-REGULATION;

EID: 40349098669     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000299095.65331.6f     Document Type: Article

References (45)

1. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993; 13:151-165.
2. Hamel E, Saxena PR. 5-Hydroxytryptamine involvement in migraine. In: The headaches. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2006:275-280.
3. Humphrey PPA. 5-Hydroxytryptamine and the patho-physiology of migraine. J Neurol 1991;238:S38-S44.
4. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 2005;65:620-622.
5. Brey RL. Both migraine and motion sickness may be due to low brain levels of serotonin. Neurology 2005; 65:E9-E10.
6. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996; 46:1404-1409.
7. Marziniak M, Mossner R, Schmitt A, Lesch KP, Sommer C. A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology 2005;64:157-159.
8. Kotani K, Shimomura T, Shimomura F, Ikawa S, Nanba E. A polymorphism in the serotonin transporter gene regulatory region and frequency of migraine attacks. Headache 2002;42:893-895.
9. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527-1531.
10. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology 1989;39:1239-1242.
11. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-660.
12. Chugani DC, Niimura K, Chaturvedi S, et al. Increased brain serotonin synthesis in migraine. Neurology 1999; 53:1473-1479.
13. Silberstein SD. Migraine. Lancet 2004;363:381-391.
14. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346: 257-270.
15. Proietti-Cecchini A, Schoenen JAJ. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997;17:849-854.
16. Thomaides T, Tagaris G, Karageorgiou C. EEG and topographic frequency analysis in migraine attack before and after sumatriptan infusion. Headache 1996;36: 111-114.
17. van der Post J, Schram MT, Schoemaker RC, et al. CNS effects of sumatriptan and rizatriptan in healthy female volunteers. Cephalalgia 2002;22:271-281.
18. Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute and chronic administration of antimigraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004;24:2-11.
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 (suppl 7):1-96.
20. Okazawa H, Leyton M, Benkelfat C, Mzengeza S, Diksic M. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan. J Psychiatry Neurosci 2000;25:359-370.
21. Rosa-Neto P, Diksic M, Okazawa H, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004;61:556-563.
22. Sakai Y, Nishikawa M, Leyton M, Benkelfat C, Young SN, Diksic M. Cortical trapping of alpha-[(11)C]methyl-l-tryptophan, an index of serotonin synthesis, is lower in females than males. Neuroimage 2006;33:815-824.
23. Spitzer RL. Structural clinical interview for DSM-IIIR. New York: New York State Psychiatric Institute, Biometrics Research Department, 1987.
24. Diksic M, Young SN. Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J Neuro-chem 2001;78:1185-1200.
25. Leyton M, Diksic M, Benkelfat C. Brain regional alpha-[11C]methyl-L- tryptophan trapping correlates with post-mortem tissue serotonin content and [11C]5-hydroxytryptophan accumulation. Int J Neuropsycho-pharmacol 2005;8:633-634.
26. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15:273-289.
27. Nishikawa M, Kumakura Y, Young SN, et al. Increasing blood oxygen increases an index of 5-HT synthesis in human brain as measured using alpha-[(11)C]methyl-L-tryptophan and positron emission tomography. Neurochem Int 2005;47:556-564.
28. Juhasz C, Chugani DC, Padhye UN, et al. Evaluation with alpha-[11C]methyl-L-tryptophan positron emission tomography for reoperation after failed epilepsy surgery. Epilepsia 2004;45:124-130.
29. Okazawa H, Tsuchida T, Pagani M, et al. Effects of 5-HT(1B/1D) receptor agonist rizatriptan on cerebral blood flow and blood volume in normal circulation. J Cereb Blood Flow Metab 2006;26:92-98.
30. Ambrosini A, Rossi P, De Pasqua V, Pierelli F, Schoenen J. Lack of habituation causes high intensity dependence of auditory evoked cortical potentials in migraine. Brain 2003 126 (pt 9):2009-2015.
31. Afra J, Proietti Cecchini A, Sandor PS, Schoenen J. Comparison of visual and auditory evoked cortical potentials in migraine patients between attacks. Clin Neurophysiol 2000;111:1124-1129.
32. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 1993;33:173-187.
33. Coppola G, Vandenheede M, Di Clemente L, et al. So-matosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain 2005;128 (pt 1):98-103.
34. Judit A, Sandor PS, Schoenen J. Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the migraine attack. Cephalalgia 2000;20:714-719.
35. Ozkul Y, Bozlar S. Effects of fluoxetine on habituation of pattern reversal visually evoked potentials in migraine prophylaxis. Headache 2002;42:582-587.
36. Diener HC, Scholz E, Dichgans J, et al. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann Neurol 1989;25:125-130.
37. Stamford JA, Davidson C, McLaughlin DP, Hopwood SE. Control of dorsal raphe 5-HT function by multiple 5-HT1 autoreceptors: parallel purposes or pointless plurality? Trends Neurosci 2000;23:459-465.
38. Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol 2005;62:1270-1275.
39. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central tri-geminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004;101:4274-4279.
40. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55:27-36.
41. Kayser V, Aubel B, Hamon M, Bourgoin S. The antimi-graine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. Br J Pharmacol 2002;137:1287-1297.
42. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-381.
43. Roberts C, Belenguer A, Middlemiss DN, Routledge C. Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur J Pharmacol 1998;346:175-180.
44. Johnson DE, Rollema H, Schmidt AW, McHarg AD. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol 2001;425:203-210.
45. Ferrari MD. Biochemistry of migraine. Path Biol 1992; 40:287-292. 440-448